Parasitaemia: P. falciparum · malaria prevention
Topical repellents showed no clear difference in parasitaemia: P. falciparum compared with placebo or no treatment (low certainty).
1 finding from 1 review
Clinical malaria: P. vivax · malaria prevention
Topical repellents showed no clear difference in clinical malaria: P. vivax compared with placebo or no treatment (low certainty).
1 finding from 1 review
Parasitaemia: P. vivax · malaria prevention
Topical repellents showed no clear difference in parasitaemia: P. vivax compared with placebo or no treatment (low certainty).
1 finding from 1 review
Clinical malaria: P. falciparum · malaria prevention
ITC may leads to lower clinical malaria: P. falciparum compared with placebo or no treatment (low certainty).
1 finding from 1 review
Clinical malaria: P. vivax · malaria prevention
ITC showed no clear difference in clinical malaria: P. vivax compared with placebo or no treatment (low certainty).
1 finding from 1 review
Parasitaemia · malaria prevention
It is very uncertain whether spatial repellents changes parasitaemia Plasmodium spp. compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of diarrhoea · children under 5 years of age
1 finding from 1 review
no estimate extracted
491 participants
Low
Recurrence · people with Buruli ulcer, non‐ulcerated lesions measuring less than 10 cm in diameter, aged 15 years or older
It is very uncertain whether rifampicin combined with streptomycin changes recurrence, 12 months compared with surgery alone (very low certainty).
1 finding from 1 review
Curea · people with Buruli ulcer, early lesions measuring less than 10 cm in diameter, aged 5 years or older
Rifampicin with clarithromycin showed no clear difference in curea compared with rifampicin with streptomycin (low certainty).
1 finding from 1 review
Cure · people who are being treated for active VL
1 finding from 1 review
Definitive cure · people who are being treated for active VL
1 finding from 1 review
Completion of treatment · people who are being treated for active VL
1 finding from 1 review
Resolution of symptoms · people who are being treated for active VL
1 finding from 1 review
Physical growth / weight gain · people who are being treated for active VL
1 finding from 1 review
Adverse outcomes · people who are being treated for active VL
1 finding from 1 review
Intervention not reported
Malaria cases per month · people of all ages
It is very uncertain whether the intervention changes malaria cases per month (very low certainty).
1 finding from 1 review
All‐cause mortality · people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever
It is very uncertain whether ribavirin changes mortality compared with no ribavirin (very low certainty).
1 finding from 1 review
Length of hospital stay · people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever
1 finding from 1 review
Requirement for transfusion (platelets) · people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever
It is very uncertain whether ribavirin changes requirement for transfusion (platelets) compared with no ribavirin (very low certainty).
1 finding from 1 review
Mortality in early versus late supportive care plus ribavirin · people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever
It is very uncertain whether early changes mortality in early versus late supportive care plus ribavirin compared with late supportive care plus ribavirin (very low certainty).
1 finding from 1 review
RR 0.39 [0.16, 0.95]
63 participants
Very low